IFNG and colitis: The supplementation of intestinal T cells from UC patients and mouse models with colitis with GlcNAc promoted the enhancement of β1,6 branching N-glycans on T cells, suppressing TCR signaling and reducing the production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ).